Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Pharm Biol ; 50(1): 30-41, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22196581

ABSTRACT

CONTEXT: Whether natural product drug discovery programs should rely on wild plants collected "randomly" from the natural environment, or whether they should also include plants collected on the basis of use in traditional medicine remains an open question. OBJECTIVE: This study analyzes whether plants with ethnomedical uses from Vietnam and Laos have a higher hit rate in bioassay testing than plants collected from a national park in Vietnam with the goal of maximizing taxonomic diversity ("random" collection). MATERIALS AND METHODS: All plants were extracted and subjected to bioassay in the same laboratories. Results of assays of plant collections and plant parts (samples) were scored as active or inactive based on whether any extracts had a positive result in a bioassay. Contingency tables were analyzed using χ(2) statistics. RESULTS: Random collections had a higher hit rate than ethnomedical collections, but for samples, ethnomedical plants were more likely to be active. Ethnomedical collections and samples had higher hit rates for tuberculosis, while samples, but not collections, had a higher hit rate for malaria. Little evidence was found to support an advantage for ethnomedical plants in HIV, chemoprevention and cancer bioassays. Plants whose ethnomedical uses directly correlated to a bioassay did not have a significantly higher hit rate than random plants. DISCUSSION: Plants with ethnomedical uses generally had a higher rate of activity in some drug discovery bioassays, but the assays did not directly confirm specific uses. CONCLUSIONS: Ethnomedical uses may contribute to a higher rate of activity in drug discovery screening.


Subject(s)
Drug Discovery/methods , Ethnobotany/methods , Plant Extracts/pharmacology , Plants, Medicinal/chemistry , Biological Assay/methods , Ethnopharmacology/methods , Humans , Laos , Medicine, Traditional , Plant Extracts/isolation & purification , Vietnam
2.
Pharm Biol ; 50(1): 42-60, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22136442

ABSTRACT

CONTEXT: An ethnobotany-based approach in the selection of raw plant materials to study was implemented. OBJECTIVE: To acquire raw plant materials using ethnobotanical field interviews as starting point to discover new bioactive compounds from medicinal plants of the Lao People's Democratic Republic. METHODS: Using semi-structured field interviews with healers in the Lao PDR, plant samples were collected, extracted, and bio-assayed to detect bioactivity against cancer, HIV/AIDS, TB, malaria. Plant species demonstrating activity were recollected and the extracts subjected to a bioassay-guided isolation protocol to isolate and identify the active compounds. RESULTS: Field interviews with 118 healers in 15 of 17 provinces of Lao PDR yielded 753 collections (573 species) with 955 plant samples. Of these 955, 50 extracts demonstrated activity in the anticancer, 10 in the anti-HIV, 30 in the anti-TB, and 52 in the antimalarial assay. Recollection of actives followed by bioassay-guided isolation processes yielded a series of new and known in vitro-active anticancer and antimalarial compounds from 5 species. DISCUSSION: Laos has a rich biodiversity, harboring an estimated 8000-11,000 species of plants. In a country highly dependent on traditional medicine for its primary health care, this rich plant diversity serves as a major source of their medication. CONCLUSIONS: Ethnobotanical survey has demonstrated the richness of plant-based traditional medicine of Lao PDR, taxonomically and therapeutically. Biological assays of extracts of half of the 955 samples followed by in-depth studies of a number of actives have yielded a series of new bioactive compounds against the diseases of cancer and malaria.


Subject(s)
Drug Discovery/methods , Medicine, Traditional , Plant Extracts/pharmacology , Plants, Medicinal/chemistry , Adult , Aged , Aged, 80 and over , Biodiversity , Biological Assay/methods , Data Collection , Ethnobotany/methods , Female , Humans , Laos , Male , Middle Aged , Phytotherapy/methods , Plant Extracts/isolation & purification
3.
J Virol ; 76(22): 11236-44, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12388683

ABSTRACT

Presently marketed vaginal barrier methods are cytotoxic and damaging to the vaginal epithelium and natural vaginal flora when used frequently. Novel noncytotoxic agents are needed to protect men and women from sexually transmitted diseases. One novel candidate is a mandelic acid condensation polymer, designated SAMMA. The spectrum and mechanism of antiviral activity were explored using clinical isolates and laboratory-adapted strains of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). SAMMA is highly effective against all CCR5 and CXCR4 isolates of HIV in primary human macrophages and peripheral blood mononuclear cells. SAMMA also inhibits infection of cervical epithelial cells by HSV. Moreover, it exhibits little or no cytotoxicity and has an excellent selectivity index. SAMMA, although not a sulfonated or sulfated polymer, blocks the binding of HIV and HSV to cells by targeting the envelope glycoproteins gp120 and gB-2, respectively, and also inhibits HSV entry postattachment. SAMMA is an excellent, structurally novel candidate microbicide that warrants further preclinical evaluation.


Subject(s)
Antiviral Agents/pharmacology , HIV-1/pathogenicity , Mandelic Acids/pharmacology , Polymers/pharmacology , Simplexvirus/pathogenicity , Antiviral Agents/toxicity , Cell Line , HIV Infections/prevention & control , HIV-1/drug effects , HIV-1/isolation & purification , Herpes Simplex/prevention & control , Humans , Leukocytes, Mononuclear/virology , Macrophages/virology , Mandelic Acids/chemistry , Mandelic Acids/toxicity , Microbial Sensitivity Tests , Polymers/toxicity , Simplexvirus/drug effects , Simplexvirus/isolation & purification
4.
Contraception ; 64(1): 67-75, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11535216

ABSTRACT

Vaginal prophylactic methodology may prevent heterosexual transmission of the HIV and other sexually transmitted disease-causing organisms as well as unplanned pregnancies. A new delivery system (ACIDFORM) was designed with acid-buffering, bioadhesive, and viscosity-retaining properties to (1) maintain the acidic vaginal milieu (the low pH inactivates many pathogens and spermatozoa), (2) form a protective layer over the vaginal/cervical epithelium (minimizing contact with pathogenic organisms), and (3) provide long-term vaginal retention. A Phase I clinical study with ACIDFORM provided initial information about its safety and showed the formation of a layer over the vaginal/cervical epithelium [1; Amaral et al., Contraception 1999;60:361-6]. To study the properties of the gel (without active ingredient) in more detail, ACIDFORM's acid-buffering, bioadhesive, viscosity-retaining, and spermicidal properties were compared in vitro to marketed formulations, and its long-term stability was assessed. ACIDFORM, either when titrated with NaOH or when mixed directly with semen, is highly acid buffering and much more effective than Aci-Jel, a commercial acid-buffering vaginal product. ACIDFORM adheres well to two model membranes (excised sheep vagina and cellophane) and is more bioadhesive than Conceptrol, Advantage S, Replens, Aci-Jel, and K-Y jelly. On dilution, ACIDFORM also retains its viscosity better than these marketed products. ACIDFORM is spermicidal and is stable for at least 2 years. These results suggest that ACIDFORM has advantages over presently marketed vaginal delivery systems. The gel may either be useful by itself as an antimicrobial contraceptive product or as a formulation vehicle for an active ingredient with antimicrobial and/or contraceptive properties.


Subject(s)
Chemistry, Pharmaceutical , HIV Infections/prevention & control , Hydrogen-Ion Concentration/drug effects , Spermatocidal Agents/therapeutic use , Acrylic Resins , Female , Humans , Male , Sexually Transmitted Diseases/prevention & control
5.
J Androl ; 22(3): 481-90, 2001.
Article in English | MEDLINE | ID: mdl-11330649

ABSTRACT

In view of the need for improved vaginal formulations that are contraceptive, that may prevent transmission of sexually transmitted infections, or both, a new delivery system (base formulation; called Long Acting, Sustained Release of Spermicide, or LASRS) was developed that contains bioadhesive and other ingredients with a long history of safety, and was designed to provide long-lasting vaginal retention of the formulation and to minimize possible vaginal irritation caused by incorporated active ingredients. Nonoxynol-9 (N-9) was added as an active ingredient to study the vaginal irritating properties of the formulation and to assess its long-term effectiveness by postcoital spermicidal tests. In the first series of experiments, in vitro studies showed that the formulation spreads rapidly over a cellulose membrane, forming a bioadhesive layer that remained for at least 12 hours. The second series of experiments addressed the safety of the LASRS suppository in rabbits and primates. Even with a very high concentration of N-9 (20.5%), LASRS caused only mild/moderate but acceptable irritation in the rabbit. No vaginal irritation occurred in the primate at an even higher concentration (22.5%). During the third series of experiments, the long-lasting vaginal retention properties were evaluated by postcoital spermicidal tests in the primate. LASRS with N-9 was highly spermicidal even when mating was delayed for 12 hours after placement of the formulation. Spermicidal activity was also observed when 1) mating was delayed for 24 hours after insertion of the formulation, and 2) if the females were mated 2 or even 3 times without reinsertion of the suppository before collection of the vaginal contents. In the final series of tests, the postcoital spermicidal properties of menfegol, another cytotoxic spermicide, were evaluated as were several modifications in the base formulation. Menfegol produced essentially the same results as N-9. Altering the base formulation proved to be nonbeneficial because a decrease in the long-term spermicidal effectiveness was obtained. These results suggest that the LASRS suppository has good vehicle properties for the delivery of active ingredients to the vagina.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Contraceptive Agents, Female/administration & dosage , Animals , Anti-Bacterial Agents/adverse effects , Contraceptive Agents, Female/adverse effects , Contraceptive Agents, Female/pharmacology , Copulation , Dose-Response Relationship, Drug , Drug Combinations , Female , Irritants/adverse effects , Macaca , Male , Nonoxynol/administration & dosage , Nonoxynol/adverse effects , Nonoxynol/pharmacology , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Polyethylene Glycols/pharmacology , Rabbits , Sperm Count , Spermatocidal Agents/administration & dosage , Spermatocidal Agents/adverse effects , Spermatocidal Agents/pharmacology , Spermatozoa/drug effects , Suppositories , Vaginal Diseases/chemically induced
6.
Contraception ; 62(2): 91-7, 2000 Aug.
Article in English | MEDLINE | ID: mdl-11102593

ABSTRACT

Pilot clinical trials were performed with a new vaginal suppository called "Long Acting, Sustained Release of Spermicide" ("LASRS"). No visual or colposcopic lesions or patient complaints occurred as a result of using LASRS with increasing doses of nonoxynol-9 (up to 20%) for 5 days or of applying the highest dose of nonoxynol-9 (20%; total 400 mg) for 8 h. Colposcopic or visual lesions were also not induced when LASRS with 20% nonoxynol-9 was used for 7 consecutive days by the study participants except for those who developed symptomatic monilia vaginitis. Symptoms were reported although these were mostly minor. A long-lasting, bioadhesive, translucent layer (film) of formulation formed over the vaginal and cervical surfaces. Postcoital spermicidal studies showed LASRS to be highly effective for prolonged periods of time. Although intercourse was delayed for 5 to 8.5 h after insertion of the formulation, an average of only 0. 2 motile sperm/HPF could be found in cervical mucus. These studies suggest LASRS to possess advantages over presently marketed formulations by having long-term efficacy and by forming a bioadhesive, presumably protective layer over the genital tract epithelium. The results also suggest the formulation to decrease the vaginal irritation caused by nonoxynol-9 as noted by colposcopy. These pilot data support a more extensive study with the LASRS suppository.


Subject(s)
Nonoxynol , Pessaries , Spermatocidal Agents/administration & dosage , Adult , Brazil , Cervix Mucus/chemistry , Coitus , Delayed-Action Preparations , Dose-Response Relationship, Drug , Female , Humans , Nonoxynol/administration & dosage , Pilot Projects
7.
J Androl ; 21(6): 862-75, 2000.
Article in English | MEDLINE | ID: mdl-11105913

ABSTRACT

A commercial preparation of a sodium polystyrene sulfonate (designated as N-PSS; its molecular weight is 500000 daltons) was tested as an inhibitor of sperm function and as a preventive agent for conception and the transmission of sexually transmitted diseases. The polymer is an irreversible inhibitor of hyaluronidase and acrosin; its IC50 values are 5.7 microg/mL and 0.5 microg/mL, for hyaluronidase and acrosin, respectively. N-PSS is also a stimulus of human sperm acrosomal loss. It produces maximal acrosomal loss at 2.5 microg/mL. Contraception in rabbits is nearly complete when rabbit spermatozoa are pretreated with 0.5 mg/mL of N-PSS before artificial insemination; however, N-PSS does not immobilize spermatozoa at concentrations as high as 50 mg/mL. N-PSS has broad spectrum antiviral and antibacterial activities. Infection by human immunodeficiency virus and herpes simplex virus are inhibited by N-PSS; 3-log reductions are produced by 7 microg/mL and 3 microg/mL, respectively. N-PSS is active against Chlamydia trachomatis and Neisseria gonorrhoeae. At 1 mg/mL, N-PSS inhibits chlamydial infectivity by more than 90%. N-PSS produces a 3-log reduction in gonococcal growth at 15 microg/mL. In contrast, N-PSS (5 mg/mL) does not affect the growth of Lactobacillus (normal component of the vaginal flora). N-PSS can be classified as a noncytotoxic contraceptive antimicrobial agent. These properties justify bringing a polystyrene sulfonate into clinical trials for its evaluation as a preventive agent for conception and several sexually transmitted diseases.


Subject(s)
Anti-Infective Agents/pharmacology , Hyaluronoglucosaminidase/antagonists & inhibitors , Polystyrenes/pharmacology , Sexually Transmitted Diseases/prevention & control , Spermatocidal Agents/pharmacology , Spermatozoa/drug effects , Animals , Anti-Bacterial Agents , Antiviral Agents/pharmacology , Chlamydia trachomatis/drug effects , Female , HIV/drug effects , Humans , Insemination, Artificial , Male , Microbial Sensitivity Tests , Neisseria gonorrhoeae/drug effects , Rabbits , Sexually Transmitted Diseases/transmission , Simplexvirus/drug effects , Spermatozoa/physiology
8.
J Infect Dis ; 181(2): 770-3, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10669374

ABSTRACT

Presently marketed vaginal barrier agents are cytotoxic and damage the vaginal epithelium and natural vaginal flora with frequent use. Novel noncytotoxic agents are needed to protect women from sexually transmitted diseases. One candidate compound is a high-molecular-mass form of soluble poly(sodium 4-styrene sulfonate) (T-PSS). The antimicrobial activity of T-PSS was evaluated in primary culture systems and in a genital herpes murine model. Results obtained indicate that T-PSS is highly effective against herpes simplex viruses, Neisseria gonorrhoeae, and Chlamydia trachomatis in vitro. A 5% T-PSS gel protected 15 of 16 mice from vaginal herpes, compared with 2 of 16 mice treated with a placebo gel. Moreover, T-PSS exhibited little or no cytotoxicity and has an excellent selectivity index. T-PSS is an excellent candidate topical antimicrobial that blocks adherence of herpes simplex virus at low concentrations, inactivates virus at higher concentrations, and exhibits a broad spectrum of antimicrobial activity.


Subject(s)
Anti-Infective Agents/therapeutic use , Polystyrenes/therapeutic use , Sexually Transmitted Diseases/prevention & control , Animals , Anti-Bacterial Agents , Anti-Infective Agents/pharmacology , Cells, Cultured , Cervix Uteri/cytology , Chlamydia trachomatis/drug effects , Chlamydia trachomatis/growth & development , Female , HeLa Cells , Heparin/pharmacology , Herpes Genitalis/drug therapy , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/growth & development , Herpesvirus 2, Human/drug effects , Herpesvirus 2, Human/growth & development , Humans , Mice , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/growth & development , Polystyrenes/pharmacology , Sexually Transmitted Diseases/microbiology , Sexually Transmitted Diseases/virology
9.
J Androl ; 19(1): 37-49, 1998.
Article in English | MEDLINE | ID: mdl-9537290

ABSTRACT

Cysteamine (beta-mercaptoethylamine, or MEA) is a thiol-reducing agent and has anti-HIV activity. Because of these properties, cysteamine was evaluated as a vaginal contraceptive and tested for its effects on sperm function and on other sexually transmitted microbes. Cysteamine was contraceptive in the rabbit. Conception was inhibited completely when sperm were pretreated with 500 microg/ml cysteamine and was inhibited by more than 60% when 7.5 mg cysteamine was applied vaginally as a suspension in 50% K-Y Jelly. Cysteamine had multiple effects on spermatozoa. Both acrosin (EC 3.4.21.10) and hyaluronidase (EC 3.2.1.35) were reversibly inhibited by cysteamine. Calculated IC50 values were 370 microg/ml and 150 microg/ml for acrosin and hyaluronidase, respectively. Cysteamine behaved as a poor spermicide when activity was measured by the 30-second Sander-Cramer test. However, sperm motility was inhibited completely when cysteamine was preincubated for 10 minutes prior to motility evaluation, at concentrations as low as 50 microg/ml. The calcium ionophore A23187-induced human acrosome reaction was inhibited by cysteamine (IC50 = 0.5 microg/ml). Neither herpes simplex virus nor Neisseria gonorrhoeae was affected by cysteamine at concentrations as high as 500 microg/ml and 100 microg/ml, respectively. Cysteamine appears to have no effect on normal vaginal flora (i.e., lactobacillus). These results, together with published data, strongly support the further development of cysteamine as a topical contraceptive anti-HIV agent.


Subject(s)
Anti-HIV Agents/pharmacology , Contraceptive Agents, Female/pharmacology , Cysteamine/pharmacology , HIV/drug effects , Acrosin/antagonists & inhibitors , Animals , Anti-HIV Agents/metabolism , Chlorocebus aethiops , Cysteamine/metabolism , HIV/metabolism , HIV Envelope Protein gp120/metabolism , Hyaluronoglucosaminidase/antagonists & inhibitors , In Vitro Techniques , Male , Microbial Sensitivity Tests , Protein Binding , Rabbits , Sperm Motility/drug effects , Spermatozoa/drug effects , Spermatozoa/enzymology , Spermatozoa/metabolism , Vero Cells
11.
Toxicol Lett ; 70(2): 155-64, 1994 Feb 01.
Article in English | MEDLINE | ID: mdl-8296320

ABSTRACT

The target cell(s) of theobromine toxicity on rat testes and reproductive toxicity induced by pure theobromine and cocoa extract are evaluated in the present studies. Theobromine (500 mg/kg x 7 days) inhibited body weight gain in treated rats. Decreased cauda epididymal sperm reserve (38%), seminiferous tubule fluid (STF) volume (33%), lactate concentration in STF (22%), inhibition of binding activity of androgen binding protein (ABP, 21%) and reduced ABP content in STF were also observed in theobromine-treated animals. Cocoa extract containing an equivalent amount of theobromine did not produce significant toxicity in treated rats. Theobromine concentrations in serum and testes from pure theobromine-treated rats were 1.8- and 1.6-fold higher, respectively, than that in rats treated with cocoa extract. The results support Sertoli cells as the primary target cells of theobromine toxicity. The lower theobromine concentrations in serum and testes of cocoa extract-treated rats could account for the lower toxicity in these animals.


Subject(s)
Cacao/toxicity , Sertoli Cells/drug effects , Theobromine/toxicity , Animals , Body Weight/drug effects , Male , Rats , Rats, Sprague-Dawley , Sertoli Cells/enzymology , Sertoli Cells/metabolism , Theobromine/blood , Theobromine/metabolism
12.
J Nat Prod ; 56(11): 2012-5, 1993 Nov.
Article in English | MEDLINE | ID: mdl-8289068

ABSTRACT

From the defatted meal of flaxseed (Linum usitatissimum), a novel phenylpropanoid glucoside, linusitamarin [1], was isolated, along with a number of known compounds. The structure of 1 was determined by spectroscopic analysis.


Subject(s)
Cinnamates/isolation & purification , Glucosides/isolation & purification , Seeds/chemistry , Cinnamates/chemistry , Glucosides/chemistry , Magnetic Resonance Spectroscopy , Spectrophotometry, Ultraviolet
13.
J Ethnopharmacol ; 38(2-3): 189-95, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8510468

ABSTRACT

A variety of pharmacological models are utilized in the evaluation of ethnomedicine. Most investigations are focused on developing new leads for therapeutic agents. However, there should be more efforts focused on the development of ethnomedicines because of their accessibility and acceptability in areas where modern medicine is not readily available. Testing methods to identify the active agents must be carefully selected utilizing information from ethnoanthropology, ethnobotany, phytochemistry, toxicology and pharmacology. New pharmacological models focused on cellular and molecular mechanisms can be used for ethnomedical evaluations but with great caution since they are based on known mechanisms of actions and limited by knowledge of the disease state.


Subject(s)
Anthropology, Cultural , Medicine, Traditional , Pharmacology/trends , Animals , Humans , Pharmacology/methods
15.
Reprod Toxicol ; 6(4): 347-53, 1992.
Article in English | MEDLINE | ID: mdl-1521008

ABSTRACT

The toxicities of theobromine and cocoa extract on the reproductive tract of male rats were compared in the present study. A cocoa powder extract containing 117 mg theobromine/g extract was prepared using 85% boiling methanol. Sprague-Dawley rats were weighed and dosed daily for 31 days with vehicle, 250 mg/kg theobromine, 2.14 g/kg cocoa extract (117 mg theobromine/g extract), or 0.43 g/kg cocoa extract by oral gavage. The animals were sacrificed on day 32. One testis and epididymis were removed and weighed. The epididymis was saved for the determination of epididymal sperm reserves. The remaining testis was fixed by whole body glutaraldehyde perfusion and processed for morphologic examination. A decrease in body weight gain and epididymal weights were observed in theobromine and high-dose cocoa-extract-treated groups. Theobromine and high-dose cocoa extract caused vacuolation within the Sertoli cell, abnormally shaped spermatids, and failed release of late spermatids in treated animals. Most of the vacuolations were found in the earlier and middle stage seminiferous tubules (stages I to VIII). However, the frequency of some parameters of testis alterations were significantly lower in the high-dose cocoa-extract-treated group compared to the theobromine-treated group. These data demonstrate the ability of a cocoa extract containing theobromine to alter testis structure in a similar pattern but with reduced intensity compared to that observed after oral exposure to pure theobromine.


Subject(s)
Cacao , Plant Extracts/toxicity , Theobromine/toxicity , Animals , Body Weight/drug effects , Chromatography, High Pressure Liquid , Genitalia, Male/drug effects , Male , Organ Size/drug effects , Rats , Rats, Inbred Strains , Testis/drug effects , Testis/pathology , Theobromine/blood
16.
Contraception ; 41(4): 411-7, 1990 Apr.
Article in English | MEDLINE | ID: mdl-2335105

ABSTRACT

The effect of ketoconazole on the fertility of male rats was evaluated. Three days of oral dosing with ketoconazole at 200 mg/kg reduced fertility compared to controls. A complete loss of fertility was observed after doses of 400 mg/kg. There was no change in the testicular weight, epididymal sperm concentration or epididymal weight between the control and treatment groups. Motility was reduced in the high-dose group and forward progression was reduced in both dosing groups compared to control. These data support previous observations in the dog and primate that orally administered ketoconazole alters sperm viability. Although ketoconazole is too toxic for contraceptive application, its derivatives may be useful for this purpose.


Subject(s)
Fertility/drug effects , Ketoconazole/pharmacology , Administration, Oral , Animals , Dose-Response Relationship, Drug , Epididymis/anatomy & histology , Ketoconazole/adverse effects , Male , Organ Size/drug effects , Rats , Rats, Inbred Strains , Sperm Motility/drug effects , Spermatozoa/drug effects , Testis/anatomy & histology
17.
J Nat Prod ; 53(2): 396-406, 1990.
Article in English | MEDLINE | ID: mdl-2166136

ABSTRACT

From the leaves and stems of Larrea tridentata six new furanoid lignans, compounds 1-6, have been isolated and their structures determined through interpretation of physical and spectroscopic properties. The use of 1D and 2D nOe experiments was of particular importance in assigning the stereochemistry.


Subject(s)
Furans/isolation & purification , Lignin/isolation & purification , Plants, Medicinal/chemistry , Animals , Embryo Implantation/drug effects , Female , Furans/pharmacology , Larrea , Lignans , Lignin/pharmacology , Magnetic Resonance Spectroscopy , Molecular Structure , Pregnancy , Rats , Rats, Inbred Strains
18.
Reprod Toxicol ; 4(2): 153-6, 1990.
Article in English | MEDLINE | ID: mdl-1726509

ABSTRACT

Two acrosin inhibitors, 4'-methylumbelliferyl 4-guanidinobenzoate and 2'-carbomethoxyphenyl 4-guanidinobenzoate, were tested for mutagenicity in the transplacental micronucleus assay and the mouse bone marrow micronucleus assay. The compounds were administered intraperitoneally at doses of 125 mg/kg and 250 mg/kg to pregnant mice. Fetal peripheral blood and maternal bone marrow cells were examined at 36 h for the frequency of micronucleated polychromatic erythrocytes. Neither compound induced micronuclei in maternal or fetal tissues. The ratio of polychromatic erythrocytes to normochromatic erythrocytes was not affected by the drug treatments indicating that the compounds had no effect on the cell cycle or mitosis in these tissues and that they were not cytotoxic. Both compounds, which show promise as vaginal contraceptives, were not mutagenic in this study.


Subject(s)
Guanidines/toxicity , Hymecromone/analogs & derivatives , Mutagens/toxicity , Animals , Bone Marrow/drug effects , Bone Marrow Cells , Erythrocytes/drug effects , Erythrocytes/ultrastructure , Female , Fetus/cytology , Hematopoietic System/cytology , Hematopoietic System/drug effects , Hymecromone/toxicity , Mice , Micronucleus Tests , Mitosis/drug effects , Placenta/cytology , Pregnancy , Staining and Labeling
19.
Prog Clin Biol Res ; 302: 129-49; discussion 150-6, 1989.
Article in English | MEDLINE | ID: mdl-2666986

ABSTRACT

Chemicals can interfere with hormonal control of the male reproductive tract and/or directly alter male reproductive tract function. A review is presented of those chemicals developed and tested as male contraceptive agents which have a direct effect on the male reproductive tract with minimal disturbance of the hormonal milieu. Such chemicals can have one or more sites of action: 1) the testis, disturbing spermatogenesis; 2) the epididymis, altering sperm maturation; 3) the vas deferens, affecting sperm transport; and 4) the accessory sex glands, entering the ejaculate and changing the functional activity of the spermatozoa. Examples of each mode of action are presented.


PIP: A review of the agents tested in animals and men and shown to have a direct nonhormonal contraceptive effect is subdivided into those affecting spermatogenesis in the testis, sperm maturation in the epididymis, transport in the vas deferens and sperm functional activity via the accessory glands. Chemicals acting in the testis, sperm functional activity via the accessory glands. Chemicals acting in the testis, and tested in men, are bis(dichloracetyl)diamines, later found to have disulfuram-like effects, and nitrofurans, which had several systemic adverse effects. Gossypol acts at this levels, probably by affecting sperm mitochondria. It requires prolonged administration by oral route, and causes hypokalemia. Lonidamine, an indazole-carboxylic acid, was tested in men without reported side effects. Other agents tested in animals are thiophenes, dinitropyrroles, nitroimidazoles, organosiloxanes, indenopyridines, 5-thio-D-glucose, glycerol, ethionine and heavy metals, such as cadmium. Compounds active in the epididymis include sulfasalazine the prostaglandin synthesis inhibitor used for inflammatory bowel disease, as well as alpha-chlorohydrin, and several 6- cholor-deoxy-sugars which have been tried in animals only. Sulfasalazine cause s reversible sperm impairment, primarily enlarged sperm heads. The antifungal agent ketoconazole, a substituted imidazole acts at the level of the accessory glands, immobilizing sperm, but it also has several toxic effects if used on a long-term basis, notably central nervous system, liver and adrenal gland damage. Analogs of ketoconazole with greater antifertility effect and lesser toxicity are being sought. The approach of searching for drugs that act on the male reproductive tract directly without affecting hormonal regulation has not produced any candidates without systemic side effects, but it is hoped that it will provide agents with reversible metabolic effects peculiar to these target tissues.


Subject(s)
Contraceptive Agents, Male/pharmacology , Genitalia, Male/drug effects , Animals , Epididymis/drug effects , Epididymis/physiology , Genitalia, Male/physiology , Male , Testis/drug effects , Testis/physiology , Vas Deferens/drug effects , Vas Deferens/physiology
20.
J Pharm Sci ; 77(5): 461-3, 1988 May.
Article in English | MEDLINE | ID: mdl-3411472

ABSTRACT

The MeOH extract of Senecio vulgaris L., administered po to rats on Days 1-10 postcoitum, significantly decreased the number of normal fetuses per pregnant rat found at autopsy on Day 16. Additional experiments showed a similar activity for its hepatotoxic constituents senecionine and senecionine N-oxide, suggesting that the latter two compounds were probably responsible for the effect seen with the extract. No antifertility effects were seen in MeOH extract-treated hamsters.


Subject(s)
Contraceptive Agents/analysis , Plants, Toxic , Pyrrolizidine Alkaloids/analysis , Senecio/analysis , Animals , Cricetinae , Female , Male , Mesocricetus , Pregnancy , Pyrrolizidine Alkaloids/isolation & purification , Pyrrolizidine Alkaloids/pharmacology , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...